WINT•benzinga•
Windtree Receives Non-Binding Letter Of Intent To Purchase Its Preclinical Oncology Drug Candidate For $7M Up Front And Up To $130M In Milestones With Up To $1.5B In Royalties
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga